[Advances in the research of anti-CD20 therapeutic monoclonal antibodies].

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Yao xue xue bao = Acta pharmaceutica Sinica

• Publication date

  2013-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 24417077
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma

  2013cited by this paper
• Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.

  2013cited by this paper
• An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab.

  2012cited by this paper
• Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

  2012influential reference
• Anti-CD 20 Antibody Therapy for B-Cell Lymphomas

  2012cited by this paper
• Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis

  2012cited by this paper
• High‐dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab‐resistant B‐cell chronic lymphocytic leukemia

  2012influential reference
• Rituximab and thalidomide combination therapy for Castleman disease

  2012cited by this paper
• Anti-CD20 antibody therapy for B-cell lymphomas.

  2012influential reference
• Novel CD20 monoclonal antibodies for lymphoma therapy

  2012cited by this paper
• Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

  2011cited by this paper
• Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.

  2011cited by this paper
• Biosimilar, biobetter and next generation therapeutic antibodies

  2011cited by this paper
• Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin’s lymphoma

  2011cited by this paper
• New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies

  2011cited by this paper
• Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

  2011cited by this paper
• The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis.

  2011cited by this paper
• Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

  2011cited by this paper
• U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.

  2011influential reference
• Phase I study of LY2469298, an Fc‐engineered humanized anti‐CD20 antibody, in patients with relapsed or refractory follicular lymphoma

  2011cited by this paper
• Rituximab resistance.

  2011cited by this paper
• Pharmacokinetic study of PUM100 after a single intravenous administration to cynomolgus monkey

  2011cited by this paper
• Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

  2011cited by this paper
• Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.

  2011cited by this paper
• The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis

  2010cited by this paper
• The future of CD20 monoclonal antibody therapy in B-cell malignancies

  2010influential reference
• Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.

  2010cited by this paper
• Evolution of anti- CD20 monoclonal antibody therapeutics in oncology

  2010cited by this paper
• U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

  2010influential reference
• Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma.

  2010cited by this paper
• Anti-CD20 monoclonal antibodies: historical and future perspectives

  2010cited by this paper
• Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects

  2010cited by this paper
• GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.

  2009cited by this paper
• Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

  2009cited by this paper
• Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.

  2009cited by this paper
• A phase 2 study of yttrium‐90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia

  2009cited by this paper
• Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis.

  2009influential reference
• Rituximab in auto‐immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study

  2009cited by this paper
• CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells

  2009cited by this paper
• Progress of CD20's Biological Function

  2009cited by this paper
• Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.

  2008cited by this paper
• New approaches of B-cell-directed therapy: beyond rituximab

  2008cited by this paper
• CD20: a regulator of cell-cycle progression of B lymphocytes.

  1994cited by this paper
• Clinical and Epidemiological Research

  year unknowncited by this paper

• No citing papers are available for this paper.